Simulations Plus: Better Quarter, Same Doubts
Source: SeekingAlpha
2026-04-15 12:14:19 ET
Thesis
Simulations Plus, Inc. ( SLP ) is a specialized company that makes software used to simulate (hence, the moniker via biosimulation ) and predict how drugs will behave during development. The last time I reviewed it, I gave it a Hold rating. This was because the company’s revenue was growing strongly, but its profit margins were shrinking and its cash flow was getting weaker, making it unclear to me how profitable it would be in the near future....
Read the full article on Seeking Alpha
For further details see:
Simulations Plus: Better Quarter, Same Doubts
Simulations Plus Inc.
NASDAQ: SLP
SLP Trading
0.0% G/L:
$18.245 Last:
219,019 Volume:
$18.23 Open:
SLP Latest News
July 06, 2026 01:27:00 pm
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
$281,347,060
16,298,587
16.67%
64
N/A
Healthcare Providers & Services
Healthcare
US
Research Triangle Park
